Central nervous system hemangiopericytoma (HPC) is a malignant vascularized mesenchymal tumor with a high rate of recurrence. Because of its rarity, few clinical characteristics and prognostic analysis information regarding recurrent HPC exist for doctors to pursue optimal outcomes. Forty-six recurrent HPC cases treated at our hospital between 2004 and 2012 were compiled into a single database based on a retrospective review of patient records, which were used to summarize the clinical characteristics. The mean survival of the recurrent HPC patients in our cohort was 41.6 ± 4.4 months, with 1-, 2-, 3-, and 4-year survival rates of 80.4, 65.2, 59.2, and 53.8 %, respectively. Thirty patients (65.2 %) suffered their first tumor recurrence, with a mean survival of 36.9 ± 4.1 months. Sixteen patients (34.8 %) suffered a second or further tumor recurrence, with a mean survival of 39.7 ± 7.0 months. Eighteen patients (39.1 %) died of all causes during the follow-up period, with a mean survival of 14.2 ± 5.6 months. Univariate and multivariate regression analyses showed that factors associated with good prognosis included recurrence age over 35 years, an interval between the first and second recurrence of more than 1 year and a clear boundary of the recurrent tumor. Gross total resection with adjuvant external beam radiotherapy could independently delay tumor recurrence of the second or more times and prolong the postoperative survival; thus, this strategy should be pursued as the initial treatment.
Central nervous system Recurrent Hemangiopericytoma Clinical characteristics Treatment Prognosis
This is a preview of subscription content, log in to check access
This study was supported by National Natural Science Foundation of China (No. 81171144) and Beijing Nova program (No. XX2012033).
Conflict of interest
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109PubMedCrossRefGoogle Scholar
Rutkowski MJ, Jian BJ, Bloch O, Chen C, Sughrue ME, Tihan T, Barani IJ, Berger MS, McDermott MW, Parsa AT (2012) Intracranial hemangiopericytoma: clinical experience and treatment considerations in a modern series of 40 adult patients. Cancer 118:1628–1636PubMedCrossRefGoogle Scholar
Chan JK, Cheuk W, Ho LC, Wen JM (2012) Recurrent meningeal hemangiopericytoma with multiple metastasis and hypoglycemia: a case report. Case Rep Med 2012:628756. Epub 2012 Sep 16Google Scholar
Vuorinen V, Sallinen P, Haapasalo H, Visakorpi T, Kallio M, Jaaskelainen J (1996) Outcome of 31 intracranial haemangiopericytomas: poor predictive value of cell proliferation indices. Acta Neurochir (Wien) 138:1399–1408CrossRefGoogle Scholar
Brunori A, Delitala A, Oddi G, Chiappetta F (1997) Recent experience in the management of meningeal hemangiopericytomas. Tumori 83:856–861PubMedGoogle Scholar
Dufour H, Metellus P, Fuentes S, Murracciole X, Regis J, Figarella-Branger D, Grisoli F (2001) Meningeal hemangiopericytoma: a retrospective study of 21 patients with special review of postoperative external radiotherapy. Neurosurgery 48:756–762 discussion 762–763PubMedGoogle Scholar
Peters KB, McLendon R, Morse MA, Vredenburgh JJ (2010) Treatment of recurrent intracranial hemangiopericytoma with SRC-related tyrosine kinase targeted therapy: a case report. Case Rep Oncol 3:93–97PubMedCrossRefGoogle Scholar
Shinder R, Jackson TL, Araujo D, Prieto VG, Guadagnolo BA, Esmaeli B (2011) Preoperative radiation therapy in the management of recurrent orbital hemangiopericytoma. Ophthal Plast Reconstr Surg 27:e126–e128PubMedCrossRefGoogle Scholar